Nautilus Biotechnology Inc (NAUT)

Form 8-K - Current report

Form ARS - Annual Report to Security Holders

Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material

Form DEF 14A - Other definitive proxy statements

Form 10-Q - Quarterly report [Sections 13 or 15(d)]

Nautilus Biotechnology Reports First Quarter 2026 Financial Results

SEATTLE, April 28, 2026 (GLOBE NEWSWIRE) -- Nautilus Biotechnology, Inc. (NASDAQ: NAUT), a company pioneering...

Nautilus Biotechnology to Announce First Quarter 2026 Financial Results on April 28, 2026

SEATTLE, April 09, 2026 (GLOBE NEWSWIRE) -- Nautilus Biotechnology, Inc. (NASDAQ: NAUT; or “Nautilus”), a...

Nautilus Biotechnology to Participate in the Investor Summit Group Virtual Conference

SEATTLE, March 24, 2026 (GLOBE NEWSWIRE) -- Nautilus Biotechnology, Inc. (NASDAQ: NAUT; or “Nautilus”), a...

Nautilus Biotechnology Announces Baylor College of Medicine as First Early Access Program Customer for Voyager Platform

• Baylor selects the Nautilus Voyager™ Platform, now available through Early Access Program, for development of...

Form SCHEDULE 13D/A - General Statement of Acquisition of Beneficial Ownership: [Amend]

Form 4 - Statement of changes in beneficial ownership of securities

Form 4 - Statement of changes in beneficial ownership of securities

Form 4 - Statement of changes in beneficial ownership of securities

Form 4 - Statement of changes in beneficial ownership of securities

Nautilus Biotechnology Appoints Proteomics Commercial Leader Amber Faust as Vice President of Sales

SEATTLE, March 02, 2026 (GLOBE NEWSWIRE) -- Nautilus Biotechnology, Inc. (NASDAQ: NAUT), a company...